NCT03087032RecruitingPhase 4
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 13 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 164 (estimated)
- First submitted
- 8 Mar 2017
- Start date
- 10 Jan 2019
- Primary completion date
- 15 Jan 2025
- Lead sponsor
- The First Affiliated Hospital of Xiamen University
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT03087032
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 164
- From 10 Jan 2019 to the primary completion date, 15 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of pancreatic disease,
- History of medullary thyroid carcinoma
- Evidence in the last 6 months of significant heart disease or stroke, including myocardial infarction, unstable angina, coronary bypass and/or percutaneous transluminal coronary angioplasty, congestive heart failure (New York Heart Association Functional Classification III-IV), or severe ischemic heart disease.
Lab values
- Creatinine clearance ≤ 30 mL/min/1.73m2,
Other
- Lipase level \> 3 times above normal,
- Preparation for pregnancy or having been in pregnancy
- Researchers believe that there are any factors that affect assessing subjects' participation in trial.
- Patients unable to cooperate in clinical trials
Who the study is looking for
- Age: 18 - 75 years old.
- BMI must be greater than 24 and less than 45 kg/m2
- Patients with type 2 diabetes who met the World Health Organization (who) diagnostic criteria (1999).
- Newly diagnosed type 2 diabetic patients with HbA1c ≥ 9.0%；or patients with uncontrolled type 2 diabetes (HbA1c ≥ 7.5% ) who have received at least two types of oral hypoglycemic drugs (the dose of each drug needs to reach the second largest dose or more), or only insulin (excluding basal-bolus insulin therapy), or insulin with oral hypoglycemic drugs.
- Signed informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The first afilliated hospital of Xiamen university Coordinator of this site? Confirm its status | Xiamen | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.